The potential economic value of a 'universal' (multi-year) influenza vaccine.

TitleThe potential economic value of a 'universal' (multi-year) influenza vaccine.
Publication TypeJournal Article
Year of Publication2012
AuthorsLee BY, H Y Tai J, McGlone SM, Bailey RR, Wateska AR, Zimmer SM, Zimmerman RK, Wagner MM
JournalInfluenza Other Respir Viruses
Volume6
Issue3
Pagination167-75
Date Published2012 May
ISSN1750-2659
KeywordsAdolescent, Adult, Aged, Child, Child, Preschool, Cost-Benefit Analysis, Female, Humans, Influenza Vaccines, Influenza, Human, Male, Middle Aged, Monte Carlo Method, Vaccination, Young Adult
Abstract

BACKGROUND: Limitations of the current annual influenza vaccine have led to ongoing efforts to develop a 'universal' influenza vaccine, i.e., one that targets a ubiquitous portion of the influenza virus so that the coverage of a single vaccination can persist for multiple years.OBJECTIVES: To estimate the economic value of a 'universal' influenza vaccine compared to the standard annual influenza vaccine, starting vaccination in the pediatric population (2-18 year olds), over the course of their lifetime.PATIENT/METHODS: Monte Carlo decision analytic computer simulation model.RESULTS: Universal vaccine dominates (i.e., less costly and more effective) the annual vaccine when the universal vaccine cost ≤ $100/dose and efficacy ≥ 75% for both the 5- and 10-year duration. The universal vaccine is also dominant when efficacy is ≥ 50% and protects for 10 years. A $200 universal vaccine was only cost-effective when ≥ 75% efficacious for a 5-year duration when annual compliance was 25% and for a 10-year duration for all annual compliance rates. A universal vaccine is not cost-effective when it cost $200 and when its efficacy is ≤ 50%. The cost-effectiveness of the universal vaccine increases with the duration of protection.CONCLUSIONS: Although development of a universal vaccine requires surmounting scientific hurdles, our results delineate the circumstances under which such a vaccine would be a cost-effective alternative to the annual influenza vaccine.

DOI10.1111/j.1750-2659.2011.00288.x
Alternate JournalInfluenza Other Respir Viruses
PubMed ID21933357
PubMed Central IDPMC3253949
Grant List1P01HK000086-01 / HK / PHITPO CDC HHS / United States
1U54GM088491-0109 / GM / NIGMS NIH HHS / United States
5R01LM009132-02 / LM / NLM NIH HHS / United States
R01 LM009132 / LM / NLM NIH HHS / United States
R01 LM009132-04 / LM / NLM NIH HHS / United States
U01 GM070708 / GM / NIGMS NIH HHS / United States
U01 GM070708-03 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
Publication Categories: